SPDR S&P Biotech (XBI) 257.60 $XBI Look for Shares of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 257.60 $XBI

Look for Shares of SPDR S&P Biotech ETF to Potentially Rebound after Yesterday's 1.41% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 4:07PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $247.78 to a high of $253.92. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $253.77 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 257.60 (+5.82)

Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 319.01 (+9.58), GRUB: 33.73 (+2.72), XBI: 257.60 (+5.82), IBB: 382.17 (+8.59), REGN: 555.04 (+15.01), CELG: 135.65 (+3.09)

XBI, ANAC, EXEL, RDUS: ETF Inflow Alert
ETFChannel.com - Thu Jul 23, 10:16AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $133.7 million dollar inflow -- that's a 4.4% increase...
XBI: 257.60 (+5.82)

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 1.69% Loss
Comtex SmarTrend(R) - Tue Jul 21, 3:58PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $262.56 to a high of $270.37. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $265.05 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 257.60 (+5.82)

SPDR S&P Biotech ETF Shares Up 17.2% Since SmarTrend's Buy Recommendation (XBI)
Comtex SmarTrend(R) - Tue Jul 21, 10:52AM CDT
SmarTrend identified an Uptrend for SPDR S&P Biotech ETF (AMEX:XBI) on May 18th, 2015 at $228.31. In approximately 2 months, SPDR S&P Biotech ETF has returned 17.21% as of today's recent price of $267.59.
XBI: 257.60 (+5.82)

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 95.23 (+1.06), FBT: 126.40 (+2.55), XBI: 257.60 (+5.82), AMGN: 173.71 (+8.17), IBB: 382.17 (+8.59), INTC: 29.00 (+0.65), CELG: 135.65 (+3.09), NFLX: 107.29 (+0.86), SPY: 209.25 (+2.46), GILD: 112.32 (+1.78), KITE: 71.59 (+2.73), RCPT: 227.90 (+0.81), JUNO: 48.72 (+0.92), TWTR: 36.18 (+1.48), AAPL: 123.73 (+0.96), Z: 79.34 (+2.43)

Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 38.78 (+1.34), XT: 25.55 (+0.30), UBIO: 19.47 (+1.23), XBI: 257.60 (+5.82), IBB: 382.17 (+8.59), LABU: 49.49 (+3.26), ZBIO: 19.32 (-1.47), CHAD: 47.78 (-0.98), YLCO: 13.30 (-0.04), LABD: 28.17 (-2.20), DRIP: 72.95 (-11.03), ASHR: 39.87 (+0.71), GUSH: 18.18 (+1.91)

After Yesterday's Rally of 2.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:29PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $255.00 to a high of $260.10. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $252.82 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 257.60 (+5.82)

It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 45.24 (+1.31), GREK: 9.62 (+0.29), XBI: 257.60 (+5.82), C: 58.24 (+0.28), IBB: 382.17 (+8.59), BAC: 17.84 (+0.17), TLT: 121.29 (-0.75), MS: 39.17 (-0.08), NFLX: 107.29 (+0.86), SPY: 209.25 (+2.46), GS: 205.74 (+0.72), JPM: 68.00 (-0.01), QQQ: 111.14 (+0.96), DIA: 176.08 (+1.85), IWM: 121.35 (+0.78), XLF: 25.06 (+0.12)

Look for Shares of SPDR S&P Biotech ETF to Potentially Rebound after Yesterday's 3.69% Sell Off
Comtex SmarTrend(R) - Wed Jul 08, 4:12PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $241.12 to a high of $249.05. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $243.30 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 257.60 (+5.82)

Noteworthy ETF Inflows: XBI, RDUS, KYTH, ZIOP
ETFChannel.com - Mon Jul 06, 10:02AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $98.7 million dollar inflow -- that's a 3.8% increase...
XBI: 257.60 (+5.82)

Top Performing ETF Areas Of 1H
Zacks Funds - Seeking Alpha - Thu Jul 02, 4:55AM CDT
Despite a long list of concerns, 2015 has so far been a great year for some corners of the investment universe. Though a harsh winter, a soaring greenback and the Fed rate hike worries took the shine away from the U.S. market in Q1, we saw strength...
BBP: 36.17 (+0.69), DXJF: 29.98 (+0.27), CNXT: 43.54 (+1.24), DXJH: 33.97 (+0.40), XBI: 257.60 (+5.82), ECNS: 48.52 (+0.52), QQQC: 22.55 (-0.06), HEDJ: 63.42 (+0.90), SBIO: 38.46 (+0.84), BBC: 36.65 (+0.47), RBL: 15.91 (+0.18), DBEZ: 28.23 (+0.49), RSX: 16.76 (+0.24), ERUS: 12.86 (+0.11), HEZU: 28.16 (+0.41), ASHS: 48.27 (+1.47)

Deforestation Impacting Pharmaceutical Industry
Global Risk Insights - at Seeking Alpha - Tue Jun 30, 3:07PM CDT
Global rainforests hold unknown treasures for fighting and curing multiple diseases. But whilst the complete destruction of the world’s remaining rainforests looms on the horizon, pharmaceutical companies are only slowly beginning to tap this...
AZN: 32.85 (+0.14), PFE: 35.37 (+1.03), MRK: 57.43 (+0.44), XBI: 257.60 (+5.82), IBB: 382.17 (+8.59), GSK: 41.71 (+0.11), BMY: 64.54 (+0.24), SNY: 53.63 (+0.30), NVS: 102.77 (+1.23)

The Pharma Pipeline: Exploring An Underestimated Investment Theme
Manning & Napier - at Seeking Alpha - Tue Jun 30, 2:43PM CDT
Worldwide equity markets have had an impressive showing since emerging from the Great Recession. The run-up in prices has coincided with equities becoming broadly more expensive. Some regions offer more attractive opportunities than others from a...
XBI: 257.60 (+5.82), IBB: 382.17 (+8.59)

40% Return In ~4 Months With Our IP Selected Healthcare Companies Since SA Publication
Innovalpha - Seeking Alpha - Tue Jun 30, 10:48AM CDT
We wanted to know how the " 17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes " performed since SA publication on February 10th 2015, namely JAZZ, SAGE, TNXP, SGYP, ASPX, XNPT, INSM, RNN, NVDQ, ZSPH, ACUR, ICPT, RDHL,...
SGYP: 8.12 (-0.07), INSM: 26.70 (+1.04), RNN: 0.53 (-0.02), RDHL: 15.41 (-0.89), XBI: 257.60 (+5.82), IBB: 382.17 (+8.59), ACUR: 0.75 (-0.03), CORI: 13.76 (+0.31), SPNC: 15.40 (-0.08), SAGE: 72.06 (+2.78), TNXP: 8.01 (-0.01), EBIO: 2.80 (-0.01), HAE: 38.62 (+0.52), JAZZ: 192.99 (+7.95), ICPT: 273.23 (+7.16)

SPDR S&P Biotech ETF Falls 3.34% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Jun 29, 5:30PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $241.30 to a high of $249.80. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $245.92 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 257.60 (+5.82)

Biotech Weekly: Top Value Biotech Picks Starting Q3 2015
Daniel Ward - at Seeking Alpha - Mon Jun 29, 10:17AM CDT

OXGN: 1.34 (+0.01), ROKA: 3.12 (unch), ECYT: 5.16 (+0.11), BOTA: 2.33 (+0.02), XBI: 257.60 (+5.82), IBB: 382.17 (+8.59), CLDN: 1.24 (unch), NVET: 4.14 (-0.45), BLPH: 3.68 (+0.29), MEIP: 1.59 (+0.04)

5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 33.61 (+1.31), XBI: 257.60 (+5.82), RTRX: 32.94 (+1.09), EGRX: 92.32 (+1.09), PRTA: 69.18 (+6.41), EXEL: 5.43 (-0.01)

XBI, KYTH, RDUS, EPZM: ETF Inflow Alert
ETFChannel.com - Thu Jun 25, 10:02AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $90.8 million dollar inflow -- that's a 3.5% increase...
XBI: 257.60 (+5.82)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 509

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 537

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 0

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 523

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 441

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 349

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 340

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 262

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 400

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Thames Ventures VCT 1 PLC Reports Unaudited NAV for 2024

Updated Category News Views 81

Thames Ventures VCT 1 PLC Releases Unaudited NAV for 2024 Thames Ventures VCT 1 PLC has provided important updates about its financial status through its unaudited net asset value (NAV). As of June 30, 2024, the NAV stands at 45.9p per share. This announcement is significant for both the company and its investors, as understanding the NAV is essential for evaluating the...

Continue Reading
Gap Inc Achieves Impressive Growth and Market Expansion

Updated Category News Views 362

Gap Inc Reports Promising Financial Results Shares of Gap Inc (GAP) saw a significant uptick in early trading on Friday following the announcement of their latest quarterly results. This positive financial report highlighted a stronger performance than expected, showcasing the company's effective strategies and management efforts. Analysts' Positive Outlook on Gap In the...

Continue Reading
The Town Lake Company's Bold New Industrial Project Launch

Updated Category News Views 226

The Town Lake Company Initiates New Industrial Development Benchmark Business Parks, a division of The Town Lake Company, has proudly initiated construction on its latest small-bay industrial project. This significant development is located at 1433 Chris Lane and will encompass an impressive 84,200 square feet of innovative tilt-wall flex industrial space. The project is...

Continue Reading
Investors Unite in Class Action Against Everus Construction Group

Updated Category News Views 330

Opportunity for Investors in Everus Construction Group, Inc. In recent developments, investors of Everus Construction Group, Inc. (NYSE: ECG) have found themselves in the midst of a class action lawsuit that has drawn considerable attention. This lawsuit targets purchases made by investors during a specified period, raising important questions about the company's...

Continue Reading
Lam Research Board Approves Quarterly Dividend Announcement

Updated Category News Views 120

Lam Research Corporation Declares New Dividend Lam Research Corporation (Nasdaq: LRCX) has recently made an important announcement regarding its financial strategy. In their latest meeting, the company's Board of Directors approved a quarterly dividend of $0.23 per share for all common stockholders. This decision reflects Lam Research's commitment to providing value to...

Continue Reading